- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- S-4 Registration of securities issued in business combination transactions
- 3.20 EX-3.20
- 3.21 EX-3.21
- 3.22 EX-3.22
- 4.12 EX-4.12
- 4.13 EX-4.13
- 4.14 EX-4.14
- 4.15 EX-4.15
- 4.16 EX-4.16
- 4.17 EX-4.17
- 4.18 EX-4.18
- 10.32 EX-10.32
- 10.33 EX-10.33
- 10.34 EX-10.34
- 10.35 EX-10.35
- 10.36 EX-10.36
- 10.37 EX-10.37
- 10.38 EX-10.38
- 10.39 EX-10.39
- 10.40 EX-10.40
- 23.1 EX-23.1
- 23.2 EX-23.2
- 99.2 EX-99.2
- 99.3 EX-99.3
- 99.4 EX-99.4
- 99.5 EX-99.5
- 99.6 EX-99.6
- EX-FILING FEES Ex-filing Fees
- 25 Sep 24 424B3 Prospectus supplement
- 16 Aug 24 424B3 Prospectus supplement
- 14 Aug 24 EFFECT Notice of effectiveness
- 12 Aug 24 S-4/A Registration of securities issued in business combination transactions (amended)
- 8 Aug 24 S-4/A Registration of securities issued in business combination transactions (amended)
- 19 Jul 24 S-4/A Registration of securities issued in business combination transactions (amended)
- 27 Jun 24 S-4/A Registration of securities issued in business combination transactions (amended)
-
13 May 24 S-4 Registration of securities issued in business combination transactions
- 8 Aug 24 Registration of securities issued in business combination transactions (amended)
- 19 Jul 24 Registration of securities issued in business combination transactions (amended)
- 27 Jun 24 Registration of securities issued in business combination transactions (amended)
- 13 May 24 Registration of securities issued in business combination transactions
- 2 Jul 20 Registration of securities issued in business combination transactions (amended)
- 16 Jun 20 Registration of securities issued in business combination transactions
Exhibit 99.4
Consent of Proposed Director
I, James Bianco, M.D., hereby consent to the following:
• | to serve as a director of Kintara Therapeutics, Inc., to be renamed TuHURA Biosciences, Inc., if the transactions contemplated by the Agreement and Plan of Merger, dated April 2, 2024, by and among Kintara Therapeutics, Inc., Kayak Mergeco, Inc., and TuHURA Biosciences, Inc., are consummated, including the merger of TuHURA Biosciences, Inc. with and into Kayak Mergeco, Inc., with TuHURA Biosciences, Inc. continuing as the surviving corporation (the “Merger”); |
• | to be named as a proposed director of Kintara Therapeutics, Inc., to be renamed TuHURA Biosciences, Inc., in the Registration Statement on Form S-4, including the joint proxy and consent solicitation statement/prospectus, to be filed by Kintara Therapeutics, Inc. in connection with the Merger, and in any and all amendments and supplements thereto (collectively, the “Registration Statement”); and |
• | to the filing of this consent as an exhibit to the Registration Statement. |
/s/ James Bianco | Date: | May 13, 2024 | ||||
James Bianco, M.D. |